References
- American Diabetes Association. Statistics About Diabetes. Available at: http://www.diabetes.org/diabetes-basics/statistics/ [Last accessed 26 July 2017]
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
- Clar C, Barnard K, Cummins E, et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010;14:1-140
- American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40:S64-74
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocr Pract 2017;23:207-38
- Whalen K, Miller S, Onge ES. The role of sodium–glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 2015;37:1150-66
- Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017;21:1-218
- Johnson & Johnson. U.S. FDA Approves Invokana (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes. 2013. Available at: https://www.jnj.com/media-center/press-releases/us-fda-approves-invokana-canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes [Last accessed 18 January 2018]
- Chambers JD, Rane PB, Neumann PJ. The impact of formulary drug exclusion policies on patients and healthcare costs. Am J Manag Care 2016;22:524-31
- Nguyen E, Weeda ER, Sobieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin 2016;32:1281-90
- Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood) 2008;27:759-69
- Huang X, Liu Z, Shankar RR, Rajpathak S. Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan. Curr Med Res Opin 2015;31:1495-500
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107
- Bradley JN, Edwards KL, Gunter JT, et al. Provider decisions and patient outcomes after premature metformin discontinuation. Diabetes Spectrum 2017;30:17-22
- Srivanichakorn W, Sriwijitkamol A, Kongchoo A, et al. Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. Diabetes Metabolic Syndrome Obes Targets Therapy 2015;8:137
- Medicare 2017 Part C & D Star Rating Technical Notes. Center for Medicare. Baltimore, MD: Centers for Medicare & Medicaid Services. 2016. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/2017_Technical_Notes_preview_1_2016_08_03.pdf [Last accessed 25 August 2017]
- PhRMA. Improving prescription medication adherence is key to better healthcare. 2011. Available at: http://phrma-docs.phrma.org/sites/default/files/pdf/PhRMA_Improving%20Medication%20Adherence_Issue%20Brief.pdf [Last accessed 25 August 2017]
- Perez-Nieves M, Kabul S, Desai U, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin 2016;32:669-80
- Hadjiyianni I, Desai U, Ivanova JI, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in Japan. Value Health 2015;18:A611-12
- Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 2014;5:225-42
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- Aagren M, Luo W. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Med Econ 2011;14:108-14
- Wu EQ, Ben-Hamadi R, Yu AP, et al. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. J Med Econ 2010;13:314-23
- Alemayehu B, Ke X, Youssef NN, et al. Esomeprazole formulary exclusion: impact on total health care services use and costs. Postgrad Med 2012;124:149-63
- H-125.991 Drug Formularies and Therapeutic Interchange. Chicago, IL: American Medical Association, 2016. Available at: https://www.ama-assn.org/ssl3/ecomm/PolicyFinderForm.pl?site¼www.ama-assn.org&uri¼/resources/html/PolicyFinder/policyfiles/HnE/H-125.991.HTM [Last accessed 20 March 2018]